Transplantation characteristics in the 4 randomized trials
| . | AML (n = 172) Bu-CY/CY-TBI . | CML (n = 316) Bu-CY/CY-TBI . | Total (n = 488) . |
|---|---|---|---|
| Trial | |||
| FHCRC | — | 73/69 | 142 |
| SFGM-TC | 55/49 | 65/53 | 222 |
| Nordic group | 37/31 | 30/26 | 124 |
| Age at transplantation, y (range) | 35 (2.5-42)/33 (26.5-39.5) | 38 (31-44)/36 (29-41) | — |
| GVHD prophylaxis | MTX + CSA | MTX + CSA | 100% |
| + Anti–IL-2R | 9:55/8:49 | 7:65/8:53 | 32:222 (14.4%) |
| . | AML (n = 172) Bu-CY/CY-TBI . | CML (n = 316) Bu-CY/CY-TBI . | Total (n = 488) . |
|---|---|---|---|
| Trial | |||
| FHCRC | — | 73/69 | 142 |
| SFGM-TC | 55/49 | 65/53 | 222 |
| Nordic group | 37/31 | 30/26 | 124 |
| Age at transplantation, y (range) | 35 (2.5-42)/33 (26.5-39.5) | 38 (31-44)/36 (29-41) | — |
| GVHD prophylaxis | MTX + CSA | MTX + CSA | 100% |
| + Anti–IL-2R | 9:55/8:49 | 7:65/8:53 | 32:222 (14.4%) |
IL-2R indicates interleukin-2 receptor; SFGM-TC, Société Française de Greffe de Moelle et de Therapie Cellulaire; MTX, methotrexate; CSA, cyclosporine.